Immunic, Inc. filings document SEC reporting for a Nasdaq-listed biotechnology company developing oral therapies for neurologic disease. Recent Form 8-K reports cover financial results and corporate updates, Nasdaq minimum bid price compliance, stockholder-approved charter amendments, and the reverse stock split affecting its common stock.
Governance disclosures include director and officer appointments, executive compensation arrangements, special-meeting voting results, and definitive proxy materials. The filings also describe registered common stock, capital-structure changes, financing and clinical-program updates, and formal governance and shareholder voting subjects tied to Immunic's late-stage development model.
Immunic, Inc. is registering 7,000,000 additional shares of common stock for issuance under its 2019 Omnibus Equity Incentive Plan, as amended. On April 20, 2025, the board approved an amendment to the plan, subject to stockholder approval, to raise the total shares authorized for issuance under the plan to 26,448,871. Stockholders approved this amendment on June 4, 2025, and this Form S-8 filing implements that approval.
The newly registered shares are of the same class as those covered by prior Form S-8 registrations and will be issuable to eligible participants in the 2019 plan. Immunic also restates its standard Delaware-law based indemnification and director-and-officer insurance protections for its directors and officers in connection with securities law liabilities.
Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh report beneficial ownership equal to 9.9% of Immunic, Inc. common stock on a fully‑diluted, exercise‑limited basis. The filing discloses that the reporting persons hold warrants to purchase 11,250,000 shares but, due to exercise limitations in the warrant terms, may only exercise for up to 9,485,936 shares, representing 9.9% of the issuer based on 95,817,536 outstanding shares. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Nantahala Capital Management, LLC and two individuals report a 9.99% beneficial interest in Immunic, Inc. The filing shows Nantahala, together with Wilmot B. Harkey and Daniel Mack, may be deemed the beneficial owners of 10,634,565 shares of Immunic common stock, representing 9.99% of the class as of June 30, 2025. The amount reported includes shares that may be acquired within 60 days through exercise of warrants. The Reporting Persons disclose shared voting and dispositive power over these shares and identify BLACKWELL PARTNERS LLC - SERIES A as a fund with the right to receive dividends or sale proceeds for more than 5% of the shares reported. The filing certifies the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control.
Biotechnology Value Fund and related entities reported combined beneficial ownership in Immunic, Inc. As of June 30, 2025 the Reporting Persons and a Partners managed account held 8,580,151 pre-funded warrants exercisable for shares and 13,335,000 new pre-funded warrants accompanied by Series A and Series B warrants. After applicable exercise blockers, BVF beneficially owned 6,268,162 shares (approximately 6.4%), BVF2 owned 3,027,105 shares (approximately 3.2%), Trading Fund OS owned 315,231 shares (0.3%) and certain aggregate entities may be deemed to own between 9.5% and 9.99% of outstanding shares. Series A and B warrants have a $0.75 exercise price; Series A expire December 31, 2025, Series B expire five years from issuance and have conditions tied to a $1.25 VWAP target. Multiple vehicles disclaim ownership of others' holdings; exercise is limited by contractual 9.9%/9.99% blockers.
Avidity-related reporting persons disclosed an aggregate 5,615,811 share position in Immunic, Inc. (IMUX), equal to 5.9% of the outstanding common stock, held with shared voting and dispositive power. The filing shows no reporting person claims sole voting or dispositive authority over these shares. A separate entity, Avidity Private Master Fund I LP, is shown with 4,699,411 shares (4.9%).
The statement explains the reported securities are directly owned by advisory clients of Avidity Partners Management LP and that none of those advisory clients may be deemed to beneficially own more than 5% of the class. The reporting persons include a disclaimer of beneficial ownership except to the extent of pecuniary interest and certify the holdings were not acquired to change or influence control of the issuer.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 10,479,337 shares of Immunic, Inc. (IMUX), representing 9.99% of the outstanding common stock. The filing states this total includes 9,080,737 shares issuable upon exercise of warrants and that the percentage is calculated on an aggregate base of 95,817,536 shares outstanding as reported in the company prospectus.
The reporting persons disclose no sole voting or dispositive power and instead report shared voting and shared dispositive power for the reported shares. The filing also certifies the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.
683 Capital Management, LLC, 683 Capital Partners, LP and Ari Zweiman (collectively the Reporting Persons) report beneficial ownership of warrants exercisable into 10,634,446 shares of Immunic, Inc. common stock. Those exercisable warrants, as disclosed, represent approximately 9.9% of the company's common stock on a diluted basis as presented in the filing. The reported position reflects shared voting and shared dispositive power over the warrants rather than sole control.
The percentage is calculated using the issuer's disclosed outstanding share base together with the maximum shares issuable upon exercise, and the warrants include a 9.99% beneficial ownership limitation that caps potential holdings.
Aberdeen Group plc and its U.S. subsidiary abrdn Inc filed a Schedule 13G on 31 Jul 2025 reporting passive ownership of Immunic, Inc. (IMUX) common stock as of 30 Jun 2025.
- Shares held: 8,243,941
- Ownership: 8.603 % of outstanding shares
- Voting power: 0 sole / 8,243,941 shared
- Dispositive power: 0 sole / 8,243,941 shared
- Filing basis: Rule 13d-1(b); abrdn Inc classified as Investment Adviser (IA, CO) and Aberdeen Group plc as Parent Holding Company (HC)
The institutions certify the stake is held in the ordinary course of business with no intent to influence control. Crossing the 5 % threshold adds a significant global asset manager to IMUX’s shareholder base, potentially enhancing liquidity and investor confidence.